{"organizations": [], "uuid": "d226830cc92b0b18177fb9897298cb87deac7d9f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?d=20180430&i=RCV004XB9&w=1200&r=RCV004XB9&t=2", "site_section": "http://feeds.reuters.com/reuters/UKVideoLatest", "section_title": "Reuters Video: Latest Videos UK", "url": "https://uk.reuters.com/video/2018/04/30/look-for-ma-activity-in-biotech-says-kev?videoId=422713252", "country": "US", "domain_rank": 408, "title": "Look for M&A activity in biotech, says Kevin Mahn", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T22:05:00.000+03:00", "replies_count": 0, "uuid": "d226830cc92b0b18177fb9897298cb87deac7d9f"}, "author": "", "url": "https://uk.reuters.com/video/2018/04/30/look-for-ma-activity-in-biotech-says-kev?videoId=422713252", "ord_in_thread": 0, "title": "Look for M&A activity in biotech, says Kevin Mahn", "locations": [], "entities": {"persons": [{"name": "reu", "sentiment": "negative"}, {"name": "kevin mahn look", "sentiment": "negative"}, {"name": "kevin mahn", "sentiment": "negative"}, {"name": "fred katayama", "sentiment": "none"}], "locations": [], "organizations": [{"name": "bst", "sentiment": "negative"}, {"name": "hennion & walsh", "sentiment": "negative"}, {"name": "cio", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "hennion & walsh's cio", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Look for M&A activity in biotech, says Kevin Mahn 05:32\nHennion & Walsh's CIO tells Reuters' Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers. ▲ Hide Transcript ▶ View Transcript\nHennion & Walsh's CIO tells Reuters' Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers. Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code https://reut.rs/2Fvo2M3", "external_links": ["https://s4.reutersmedia.net/resources/r/?d=20180430&i=RCV004XB9&w=576&r=RCV004XB9&t=2", "https://reut.rs/2KrRhTS"], "published": "2018-04-30T22:05:00.000+03:00", "crawled": "2018-05-01T00:23:03.033+03:00", "highlightTitle": ""}